Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Deckers Outdoor Corp (DECK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Deckers Outdoor Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Deckers Outdoor Corp trades at $106.51 (market cap $14.72B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.7× Deckers Outdoor Corp's market cap, and Deckers Outdoor Corp is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | DECK | |
|---|---|---|
Market Cap | $39.89B | $14.72B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $123.91 |
52-Week Low | $278.09 | $79.54 |
Enterprise Value | $38.15B | $13.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
DECK trades at $105.99, up 1.66% today, with a bearish technical signal but strong fundamentals. Revenue grew to $4.99B in 2025, with net income reaching $966M and profit margin expanding to 19.37%. Recent quarters show consistent earnings beats, including Q1 2026 EPS of $0.96 versus $0.83 expected. Cash flow from operations remains robust at $1.04B, supporting financial stability.
The stock offers upside to the $121.50 consensus price target, driven by HOKA and UGG global growth. Risks include competitive pressures and volatile technical indicators. Analyst sentiment is mixed with 41.82% buy ratings, but institutional holdings suggest long-term confidence amid near-term bearish signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Deckers Outdoor Corp
Deckers Outdoor Corp designs and sells casual and performance footwear, apparel, and accessories. Primary brands include UGG, Teva, and Sanuk. The company distributes Most of its products through its wholesale business, but it also has a substantial direct-to-consumer business with its company-owned retail stores and websites. Most sales are in the United States, although the company also has retail stores and distributors throughout Europe, Asia, Canada, and Latin America. Deckers sources its products from independent manufacturers primarily in Asia.
Read more on DECK →
